Premium
Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A 2 expression in HepG2 cells
Author(s) -
Ikegami Tadashi,
Matsuzaki Yasushi,
Fukushima Sugano,
Shoda Junichi,
Olivier Jean Luc,
Bouscarel Bernard,
Tanaka Naomi
Publication year - 2005
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.20630
Subject(s) - ursodeoxycholic acid , proinflammatory cytokine , arachidonic acid , medicine , endocrinology , bile acid , phospholipase a2 , hepatology , chemistry , inflammation , biochemistry , enzyme
Abstract Phospholipase A 2 IIA (PLA 2 IIA), which plays a crucial role in arachidonic acid metabolism and in inflammation, is upregulated under various pathological conditions, including in the gallbladder and gallbladder bile from patients with multiple cholesterol gallstones, in the liver and kidney of rats with cirrhosis, as well as in the colonic tissue of animals treated with a chemical carcinogen. The administration of ursodeoxycholic acid (UDCA) partially attenuated the PLA 2 IIA expression level in these different models. The aim of this study was to investigate the modulatory effect of UDCA on the PLA 2 IIA expression level at the cellular level. The HepG2 cells were selected to investigate the direct inhibitory effect of UDCA on PLA 2 IIA expression level. The proinflammatory cytokines (interleukin‐6 and tumor necrosis factor α) ‐induced PLA 2 IIA expression in HepG2 cells was partially inhibited by the presence of UDCA in a dose‐dependent fashion. The effect of UDCA on proinflammatory cytokines‐induced PLA 2 IIA expression occurred at the transcriptional level. In addition, among the bile acids tested, this inhibitory effect was UDCA‐specific. In conclusion , this study supports the possible alteration of arachidonic acid metabolism and PLA 2 IIA expression level, in particular, as the protective action of UDCA in patients with chronic liver disease. (H EPATOLOGY 2005;41:896–905.)